{"id":"dcv","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DCV (daclatasvir) binds to the NS5B polymerase of hepatitis C virus, preventing the enzyme from synthesizing viral RNA. This direct inhibition of a non-structural viral protein stops the replication cycle of HCV. It is typically used in combination with other direct-acting antivirals to achieve sustained virologic response.","oneSentence":"DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:43.828Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals"}]},"trialDetails":[{"nctId":"NCT05809752","phase":"PHASE1","title":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-22","conditions":"Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer","enrollment":18},{"nctId":"NCT05992077","phase":"NA","title":"Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia","status":"ACTIVE_NOT_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-08-07","conditions":"HCV Infection","enrollment":21000},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":"COVID-19","enrollment":192},{"nctId":"NCT04943588","phase":"","title":"Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-11-01","conditions":"Hepatitis C, Chronic","enrollment":25000},{"nctId":"NCT04108351","phase":"NA","title":"Development and Validation of a Driving Simulator for Evaluating the Residual Effects of Drugs on Driving Performance - Sensitivity Analysis Using Zopiclone As a Positive Control","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2019-10-07","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT03413592","phase":"NA","title":"Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2018-01-22","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT03278080","phase":"NA","title":"Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2017-09-22","conditions":"Healthy Participants","enrollment":20},{"nctId":"NCT03572985","phase":"NA","title":"Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #3","status":"COMPLETED","sponsor":"Taisho Pharmaceutical Co., Ltd.","startDate":"2018-06-27","conditions":"Healthy Participants","enrollment":25},{"nctId":"NCT06829966","phase":"","title":"Impact of Direct-acting Antiviral Drugs on The Patterns of Gut Microbiota in Patients With HCV Related Chronic Liver Diseases","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-05-13","conditions":"Intestinal Microbiota Between Different Groups","enrollment":30},{"nctId":"NCT02262728","phase":"PHASE2","title":"An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-30","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT04487756","phase":"PHASE1, PHASE2","title":"Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto Oncológico Dr Rosell","startDate":"2021-03-17","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT03537196","phase":"PHASE4","title":"DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-11-13","conditions":"Hepatitis C, Drug Use, Viral Hepatitis C","enrollment":979},{"nctId":"NCT02292706","phase":"","title":"A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2014-12-29","conditions":"Hepatitis C Virus Infection","enrollment":1609},{"nctId":"NCT02992457","phase":"PHASE4","title":"Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection","status":"COMPLETED","sponsor":"Tanta University","startDate":"2015-01","conditions":"Hepatitis C","enrollment":10000},{"nctId":"NCT03612973","phase":"NA","title":"Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Chronic Hepatitis c","enrollment":80},{"nctId":"NCT01866930","phase":"PHASE3","title":"Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-07-11","conditions":"Chronic Hepatitis C Infection","enrollment":453},{"nctId":"NCT05854511","phase":"PHASE3","title":"Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-06-05","conditions":"HCV","enrollment":30},{"nctId":"NCT04386252","phase":"PHASE1, PHASE2","title":"Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults","status":"WITHDRAWN","sponsor":"Aivita Biomedical, Inc.","startDate":"2023-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT02596880","phase":"PHASE3","title":"Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-09","conditions":"Hepatitis C, Cirrhosis","enrollment":100},{"nctId":"NCT03540212","phase":"PHASE2, PHASE3","title":"Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2017-12-10","conditions":"Chronic HCV Infection","enrollment":50},{"nctId":"NCT05616598","phase":"PHASE2, PHASE3","title":"Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-01","conditions":"Male Infertility, HCV","enrollment":200},{"nctId":"NCT01946373","phase":"PHASE1","title":"T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2013-10","conditions":"Melanoma","enrollment":20},{"nctId":"NCT04852614","phase":"","title":"Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Hepatitis C Virus Infection","enrollment":10},{"nctId":"NCT03882307","phase":"EARLY_PHASE1","title":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10","conditions":"Hepatitis C, Chronic","enrollment":40},{"nctId":"NCT02333292","phase":"","title":"Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2014-12","conditions":"Chronic Hepatitis C Infection","enrollment":1128},{"nctId":"NCT04561063","phase":"PHASE2","title":"COVID-19 Prophylaxis South Africa (COVER HCW)","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-08","conditions":"Covid19, SARS-CoV Infection","enrollment":1950},{"nctId":"NCT03208322","phase":"","title":"Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2018-11-30","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT05372874","phase":"","title":"Treatment of Hepatitis c by Using Direct-acting Antiviral","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-05-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03483987","phase":"NA","title":"Re-treatment of HCV Following DAA Failure","status":"TERMINATED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2018-02-10","conditions":"Chronic Hepatitis C","enrollment":18},{"nctId":"NCT03071133","phase":"","title":"Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-01","conditions":"Hepatitis C","enrollment":344},{"nctId":"NCT02727933","phase":"","title":"Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-03","conditions":"Hepatitis C","enrollment":1941},{"nctId":"NCT03706898","phase":"PHASE1","title":"Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-10-01","conditions":"HIV-1-infection, Hepatic Impairment","enrollment":36},{"nctId":"NCT03158857","phase":"","title":"Hepatitis C Treatment Study in Myanmar","status":"WITHDRAWN","sponsor":"Myanmar Oxford Clinical Research Unit","startDate":"2022-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT04690387","phase":"PHASE1","title":"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","status":"COMPLETED","sponsor":"Aivita Biomedical, Inc.","startDate":"2020-12-07","conditions":"COVID-19","enrollment":27},{"nctId":"NCT05138523","phase":"","title":"Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)","status":"COMPLETED","sponsor":"Beker Laboratories","startDate":"2019-11-21","conditions":"Chronic Hepatitis c","enrollment":99},{"nctId":"NCT04888611","phase":"PHASE2","title":"Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-10-26","conditions":"Recurrent Glioblastoma","enrollment":40},{"nctId":"NCT03500562","phase":"","title":"Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-05-08","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT05007496","phase":"PHASE2","title":"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","status":"COMPLETED","sponsor":"Aivita Biomedical, Inc.","startDate":"2021-04-14","conditions":"COVID-19","enrollment":145},{"nctId":"NCT02640157","phase":"PHASE3","title":"A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12","conditions":"Chronic Hepatitis C, Hepatitis C Virus, Genotype 3 Hepatitis C Virus","enrollment":506},{"nctId":"NCT04952207","phase":"","title":"Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Qing XIe","startDate":"2019-03-06","conditions":"Hepatitis C, Chronic","enrollment":300},{"nctId":"NCT03480932","phase":"PHASE2, PHASE3","title":"Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-02-02","conditions":"Hepatitis C, Chronic","enrollment":150},{"nctId":"NCT03487848","phase":"PHASE2","title":"Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-06-25","conditions":"Hepatitis C, Chronic Hepatitis","enrollment":5},{"nctId":"NCT03883698","phase":"PHASE3","title":"Safety of Sofosbuvir in People With Advanced Kidney Failure","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2019-03-15","conditions":"Kidney Failure, Chronic, Hepatitis C","enrollment":30},{"nctId":"NCT04773756","phase":"PHASE4","title":"Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-11-01","conditions":"Covid19","enrollment":54},{"nctId":"NCT04535869","phase":"PHASE3","title":"Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-12-28","conditions":"COVID-19","enrollment":50},{"nctId":"NCT04113629","phase":"NA","title":"Simplified Monitoring Myanmar SM2 Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-01-22","conditions":"Hepatitis C, Liver Cirrhoses, Liver Inflammation","enrollment":200},{"nctId":"NCT03669835","phase":"NA","title":"The Sublimated Mare Milk Supplement in Hepatitis C","status":"COMPLETED","sponsor":"Asfendiyarov Kazakh National Medical University","startDate":"2018-03-28","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT04729153","phase":"","title":"Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02","conditions":"Covid19","enrollment":100},{"nctId":"NCT04685603","phase":"PHASE1","title":"Dendritic Cell Vaccine to Prevent COVID-19","status":"UNKNOWN","sponsor":"Indonesia-MoH","startDate":"2020-12-07","conditions":"COVID-19","enrollment":27},{"nctId":"NCT04664894","phase":"","title":"Direct Acting Anti-Viral's In Chronic HCV Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2018-05-15","conditions":"Safety Issues","enrollment":511},{"nctId":"NCT04460443","phase":"PHASE2, PHASE3","title":"Sofosbuvir in Treatment of COVID 19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-08-01","conditions":"COVID","enrollment":60},{"nctId":"NCT02565888","phase":"PHASE1","title":"A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-11","conditions":"Hepatitis C, HIV","enrollment":16},{"nctId":"NCT02565862","phase":"PHASE1","title":"A Drug-drug Interaction Study Between Daclatasvir and Metformin","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2016-01","conditions":"Hepatitis C, Diabetes Mellitus, Insulin Resistance","enrollment":20},{"nctId":"NCT04497649","phase":"PHASE2, PHASE3","title":"Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-07-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT02170727","phase":"PHASE3","title":"A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06-26","conditions":"Hepatitis C Virus","enrollment":199},{"nctId":"NCT03283176","phase":"","title":"Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-03-01","conditions":"Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals","enrollment":50},{"nctId":"NCT01995266","phase":"PHASE3","title":"Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02-28","conditions":"Hepatitis C","enrollment":218},{"nctId":"NCT02175966","phase":"PHASE2","title":"Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-07-28","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT01741545","phase":"PHASE3","title":"Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-31","conditions":"Hepatitis C Virus","enrollment":71},{"nctId":"NCT04457050","phase":"PHASE4","title":"Effect of Hepatitis C Clearance on Insulin Resistance","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2017-10-30","conditions":"Insulin Resistance, Hepatitis C","enrollment":160},{"nctId":"NCT04443725","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-07","conditions":"COVID-19","enrollment":100},{"nctId":"NCT03366610","phase":"","title":"Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-04-28","conditions":"Hepatitis C","enrollment":199},{"nctId":"NCT04387526","phase":"PHASE2, PHASE3","title":"Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2016-04-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":946},{"nctId":"NCT04387539","phase":"PHASE1, PHASE2","title":"ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":94},{"nctId":"NCT03794258","phase":"PHASE2","title":"Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection","status":"WITHDRAWN","sponsor":"Humanity & Health Medical Group Limited","startDate":"2019-05-01","conditions":"HCV Infection","enrollment":""},{"nctId":"NCT04019717","phase":"PHASE2","title":"Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2019-06-20","conditions":"Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C","enrollment":10},{"nctId":"NCT04122066","phase":"","title":"the Pulmonary Safety of Antihepatitis C Treatment","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03181074","phase":"","title":"Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10-21","conditions":"Hepatitis C","enrollment":10},{"nctId":"NCT04244383","phase":"PHASE4","title":"Expression of Inflammasomes in HCV Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-01","conditions":"Hepatitis C","enrollment":50},{"nctId":"NCT03166943","phase":"NA","title":"the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-05-10","conditions":"Hepatitis","enrollment":130},{"nctId":"NCT04211844","phase":"","title":"Metabolic Changes in Chronic HCV Patients Receiving DAAS","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT04213612","phase":"PHASE1","title":"DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-12-30","conditions":"Unrecognized Condition","enrollment":21},{"nctId":"NCT01492504","phase":"","title":"Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-02-07","conditions":"Hepatitis C","enrollment":1850},{"nctId":"NCT04159246","phase":"","title":"Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir in Patients With Hepatitis C","status":"UNKNOWN","sponsor":"Mohamed Saad","startDate":"2019-02-10","conditions":"HCV Infection","enrollment":30},{"nctId":"NCT02709993","phase":"PHASE1, PHASE2","title":"Consolidation Therapy in Patients With Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Cancer, Hematologic Malignancies","enrollment":""},{"nctId":"NCT03063879","phase":"PHASE4","title":"Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2017-04-01","conditions":"Hepatitis C, Chronic, Chronic Renal Failure","enrollment":95},{"nctId":"NCT03163849","phase":"PHASE3","title":"Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-09-01","conditions":"Chronic Hepatitis c","enrollment":50},{"nctId":"NCT04070235","phase":"PHASE2, PHASE3","title":"SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2019-03-29","conditions":"Hepatitis C, Chronic","enrollment":440},{"nctId":"NCT03748745","phase":"PHASE1","title":"A Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2018-11-19","conditions":"Drug Interactions","enrollment":28},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT03423641","phase":"","title":"An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2011-01-01","conditions":"Hepatitis C, Chronic","enrollment":33808},{"nctId":"NCT03481036","phase":"NA","title":"DAA Therapy in Pediatric Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT03488485","phase":"NA","title":"Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-06-18","conditions":"Chronic Hepatitis c","enrollment":50000},{"nctId":"NCT03965286","phase":"","title":"Effect of Direct AntiViral Drugs of Chronic HCV on eGFR in Assuit Universiry Hospital","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-06-01","conditions":"Antiviral Drug","enrollment":80},{"nctId":"NCT02304159","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics","status":"COMPLETED","sponsor":"Tarek I. Hassanein, M.D., FACP, FAG, AGAF","startDate":"2015-01","conditions":"Hepatitis C, Cirrhosis","enrollment":39},{"nctId":"NCT03887637","phase":"","title":"Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-03-30","conditions":"Chronic Hepatitis C","enrollment":180},{"nctId":"NCT03549832","phase":"NA","title":"Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-01-01","conditions":"HCV Coinfection","enrollment":40},{"nctId":"NCT03369327","phase":"PHASE3","title":"Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2017-01-01","conditions":"Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus","enrollment":232},{"nctId":"NCT03200184","phase":"PHASE4","title":"Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2016-09-01","conditions":"Hepatitis C","enrollment":1448},{"nctId":"NCT03004625","phase":"PHASE3","title":"Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2016-11","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT03485846","phase":"PHASE2","title":"Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2017-11-27","conditions":"Chronic Hepatitis C Genotype 1b","enrollment":105},{"nctId":"NCT03547895","phase":"NA","title":"Management of Decompensated HCV Cirrhotic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2015-06-01","conditions":"Decompensated Cirrhosis","enrollment":80},{"nctId":"NCT01938625","phase":"PHASE2","title":"A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2013-12-12","conditions":"Hepatitis C, Chronic","enrollment":35},{"nctId":"NCT03686722","phase":"PHASE1","title":"Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin","status":"COMPLETED","sponsor":"Mohamed Raslan","startDate":"2017-09-09","conditions":"Diabetes Mellitus, Type 2, Hepatitis C, Drug Interactions","enrollment":20},{"nctId":"NCT03490097","phase":"PHASE2, PHASE3","title":"Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-12-01","conditions":"Chronic Hepatitis c, Metabolic Syndrome","enrollment":100},{"nctId":"NCT03665766","phase":"","title":"Effect of Cyclosporine A Versus Tacrolimus on Response to Antiviral Therapy After Hepatitis C Genotype -4 Recurrence Post Liver Transplantation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-05-15","conditions":"Liver Transplantation","enrollment":126},{"nctId":"NCT02223312","phase":"PHASE1, PHASE2","title":"Therapy for Progressive and/or Refractory Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Cancer, Hematologic Malignancies","enrollment":""},{"nctId":"NCT02705703","phase":"PHASE1, PHASE2","title":"Consolidation Therapy in Patients With Metastatic Solid Malignancies","status":"WITHDRAWN","sponsor":"Kiromic BioPharma Inc.","startDate":"2017-07-28","conditions":"Cancer, Metastatic Solid Malignancies","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"EMBOLISM"},{"count":1,"reaction":"HYPERGLYCAEMIA"},{"count":1,"reaction":"INFLUENZA LIKE ILLNESS"},{"count":1,"reaction":"OROPHARYNGEAL PAIN"},{"count":1,"reaction":"PAIN"},{"count":1,"reaction":"PERIPHERAL EMBOLISM"}],"_approvalHistory":[],"publicationCount":1089,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DCV","genericName":"DCV","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication. Used for Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}